bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P2-02-02: Lack of screening mammography and black race are associated with late-stage breast cancer diagnosis in safety-net setting
Authors: Mendez Marissa A , Cheng An-Lin , Ahmadiyeh Nasim 
Published: March 2020

Abstract
Importance: In our urban safety-net hospital (SNH) setting, we see approximately three times more late-stage (stage III and IV) breast cancer at diagnosis than the rest of the country. Breast cancers diagnosed at later stages have lower survival than those diagnosed at earlier stages. The aim of this study is to determine the factors associated with late-stage breast cancer diagnosis in our SNH setting. Method: This is a retrospective study of all breast cancer cases diagnosed or treated at the primary SNH in the Kansas City, MO metro area between January 2011-July 2018 (n=615). All female breast cancer patients diagnosed with early-stage (stage 0 or I, n=314) or late-stage (stage III or IV, n=98) disease were included. Those diagnosed at stage II (n=176), recurrent breast cancer (n=20) or with conflicting or unknown stage (n=27) were excluded. Variables analyzed: clinical TNM stage at diagnosis, age, race, insurance type, zip code, tumor subtype, whether patient presented with symptoms, whether a screening mammogram was obtained in the two years prior to diagnosis, and whether the patient was referred from outside our institution, or internally. Median household income and distance to treating facility were imputed from patient-level zipcode data. Multiple logistic regression was performed to determine the variables that contributed the most to the late-stage at diagnosis. Results: Three variables were significantly associated with late-stage diagnosis in the multiple regression: not having had a screening mammogram within two years (p&lt;0.0001, OR 0.132, CI= 0.063, 0.277), being black (p= 0.0051, OR 2.549, CI = 1.325, 4.904), and having HER2 positive disease (p=0.0213, OR=2.695, CI= 1.159, 6.265). A race by tumor marker interaction was examined, and was not found to be significant. Conclusions: In our safety-net hospital setting, not having a screening mammogram in the two years prior to a breast cancer diagnosis was the most significant factor associated with late-stage at diagnosis, followed by being black. Screening mammography ought to be actively promoted in safety-net hospital settings with excess late-stage diagnosis. Black women may need different risk-based screening guidelines.
Citation Format: Marissa A Mendez, An-Lin Cheng, Nasim Ahmadiyeh. Lack of screening mammography and black race are associated with late-stage breast cancer diagnosis in safety-net setting [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-02-02.
Abstract P2-13-04: Risk of osteoporosis and osteoporotic fracture in breast cancer survivors: A nation-wide study
Authors: Chung Il Yong , Lee Jihyoun , Alqudaihi Heba , Lee Jong Won , Son Byung Ho , Ahn Sei Hyun , Lee Ji Sung 
Published: March 2020

Abstract
Background: Referring to American Society of Clinical Oncology (ASCO) 2015 guidelines, they recommend bone screening every two years for premenopausal women receiving tamoxifen, considering it as a risk factor for developing osteoporosis. This nationwide study aimed to investigate the incidence of osteoporosis and osteoporotic fractures, and to assess whether the known factors increase the risk of osteoporosis and/or osteoporotic fractures among breast cancer survivors in South Korea.
Methods: A nationwide retrospective study was conducted using the Health Insurance Review and Assessment Service (HIRA) data. The incidence rates of osteoporosis and osteoporotic fracture were calculated by dividing the number of incident cases by the total follow-up period (person-years). The risk factors for osteoporosis and osteoporotic fracture were investigated using Cox proportional hazard regression models.
Results: From Jan 2009 to Dec 2014, a total of 47,649 breast cancer survivors were included in this analysis. During the study period, 5,955 osteoporosis events were observed from 252,396 person-year. The incidence rate of osteoporosis in breast cancer survivors was 23.59 per 1000 person-year (95% CI 23.00 - 24.20). Osteoporotic fracture incidence was assessed 2.40 per 1000 person-year (95% CI 2.23 - 2.60), with 647 events out of 269,075 person-years. In age&lt;40 subgroup, use of ovarian function suppression (OFS) was significantly related to incidence of osteoporosis (Incidence rate 7.06 95% CI 5.47 - 9.11). However, the use of tamoxifen did not show an increased risk of osteoporosis (HR 1.24, 95% CI 0.85 - 1.82). Nine osteoporotic fracture was found in 7,121 patients in age under 40. In 40-49 age group, use of chemotherapy (HR 1.41, 95% CI 1.24-1.60, p&lt;.0001), aromatase inhibitor (HR 2.45, 95% C.I. 2.05- 2.92, p&lt;.0001), and OFS (HR 1.19, 95% CI 1.01-1.40, p =.0113) showed a significant increase of osteoporosis. Osteoporotic fracture were associated with use of AI and OFS in 40-49. Use of tamoxifen significantly decreased osteoporosis diagnosis in age 40-49, 50-59, and 60-69. Tamoxifen was also related to decreased incidence of osteoporotic fracture in age 40-49 (HR 0.49, 95% CI 0.31-0.76, p&lt;.0001) and 50-59 (HR 0.37, 95% CI 0.23-0.60, p&lt;.0001).
Conclusions: Tamoxifen is not associated with the increased risk of osteoporosis and osteoporotic fracture in breast cancer survivors.
Keywords: Breast Neoplasms, Survivorship, Osteoporosis, Bone Fractures, adverse effects
Citation Format: Il Yong Chung, Jihyoun Lee, Heba Alqudaihi, Jong Won Lee, Byung Ho Son, Sei Hyun Ahn, Ji Sung Lee. Risk of osteoporosis and osteoporotic fracture in breast cancer survivors: A nation-wide study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-13-04.
Abstract P3-05-08: Sortilin-related receptor regulates receptor tyrosine kinase traffic and signaling
Authors: Akhrass Hussein Al , Conway James , Barok Mark , Andersen Olav , Ivaska Johanna 
Published: March 2020

Abstract
Understanding the mechanisms of resistance to targeted therapies is a major challenge in epidermal growth factor receptor 2 (ERBB2)-amplified breast cancer and acquired resistance to ERBB2 inhibition is a common feature of recurrent tumors. In such a setting, the activation of intracellular oncogenic signaling pathways, through alternative growth factor receptors, adds a layer of complexity to therapeutic options. Our aim is to scrutinize the intracellular retrograde transport of ERBB-family receptors and to assess whether the key sorting proteins involved within this pathway represent a potential vulnerability in ERBB2-amplified breast cancer. Sortilin-related receptor (SorLA; SORL1) is a vacuolar protein sorting 10 (VPS10)-domain receptor well characterized for its role in Alzheimer’s and metabolic diseases. In a previous study, we demonstrated a previously unknown role of SorLA in cancer. SorLA increases ERBB2 stability by stimulating its recycling from endosomes back to the plasma membrane thus sustaining ERBB2 oncogenic signaling in vitro. In an orthotopic xenograft model, SorLA silencing inhibits tumor growth adding translational relevance for SorLA targeting in breast cancer. Here we investigate possible crosstalk inputs from other growth factor receptors, and we evaluate the potential of SorLA inhibition as a unique strategy to halt the progression of ERBB2-amplified tumors.
Citation Format: Hussein Al Akhrass, James Conway, Mark Barok, Olav Andersen, Johanna Ivaska. Sortilin-related receptor regulates receptor tyrosine kinase traffic and signaling [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-05-08.
Abstract P3-07-09: The preoperative systemic inflammatory response as a strong prognostic factor in breast cancer patients
Authors: Yamashita Nami , Akiyoshi Sayuri , Sano Eiki , Shigechi Tomoko , Hisamatsu Yuichi , Tokunaga Eriko , Oki Eiji , Mori Masaki 
Published: March 2020

Abstract
Background: Recent reports show that the preoperative systemic inflammatory response status correlate with the survival rate in cancer patients. The Prognostic Nutritional Index (PNI), Controlling Nutritional Status (CONUT), Neutrophil Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) score are used as screening tools for immunonutritional status and reported to be a predictor of postoperative recurrence in patients with various gastrointestinal cancers. However, the clinical importance of these scoring in breast cancer has not been fully elucidated. The aim of this study is to investigate the clinical impact of preoperative systemic inflammatory response on long-term survival of breast cancer patients. Patients and Methods: We retrospectively analyzed 653 consecutive stage I-III breast cancer patients who were treated from January 2002 to December 2013. The PNI score was calculated as 10 x serum albumin (g/dl) + 0.005 x total lymphocyte count (per mm3). The CONUT score is calculated from three parameters, serum albumin, cholesterol, and total lymphocytes count. The patients were divided into two groups according to each value. The uni- and multivariate Cox regression analyses were performed to evaluate the prognositic value of the systemic inflammatory response in breast cancer. Results: The malnutritional or high SIR status was observed in 170 (26%),131 (20%), 119 (18%) and 226 (35%) patients as low-PNI, high-CONUT, elevated NLR and PLR, respectively. The relapse-free survival (RFS) and overall survival (OS) rates were significantly lower in the low-PNI group (RFS: p&lt;0.0001, OS: p&lt;0.0001) and high-CONUT group (RFS: p=0.0009, OS: p=0.0018). No significant association was found between NLR, PLR and prognosis. In the multivariate analysis, low-PNI was the independent prognostic factors for OS (HR4.71, p=0.0023). In the subset analysis, the low-PNI group showed poor prognosis especially in the postmenopausal, hormone receptor negative patients. The low-PNI also had poorer prognosis in post-recurrence survival. Conclusions: The preoperative systemic inflammatory response, especially PNI, is a strong independent predictor of long-term survival among breast cancer patients.
Citation Format: Nami Yamashita, Sayuri Akiyoshi, Eiki Sano, Tomoko Shigechi, Yuichi Hisamatsu, Eriko Tokunaga, Eiji Oki, Masaki Mori. The preoperative systemic inflammatory response as a strong prognostic factor in breast cancer patients [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-07-09.
Abstract P3-08-39: Pathological complete response following neoadjuvant chemotherapy in operable breast cancer patients: Is obesity a predictive factor?
Authors: Wang Haiyun , Zhang Shijia , Yee Douglas , Beckwith Heather , Potter David , Blaes Anne 
Published: March 2020

Abstract
Background: Overweight and obesity are associated with greater disease-specific mortality and overall mortality in cancer patients. Neoadjuvant chemotherapy offers a unique setting to assess breast cancer chemosensitivity in vivo, and thus can help us understand why obesity is associated with poor prognosis in breast cancer patients. The effect of increased Body mass index (BMI) in breast cancer patients undergoing neoadjuvant chemotherapy remains controversial.
Purpose: To review and analyze the association between BMI and pathological complete response (pCR) rate for operable breast cancer after neoadjuvant chemotherapy (NACT).
Data sources: Pub Med and Cochrane Database to December 31, 2018
Study selection: We included observational studies and randomized trials that evaluated association of BMI with pCR in operable breast cancer patients that underwent NACT.
Data extraction and analysis: Two authors independently extracted data and rated study quality; discrepancies were resolved through consensus.
Results: We identified 13 studies including a total of 14179 women with operable breast cancer who underwent NACT. Among them, two studies were pooled analysis of prospective clinical trials (10622 patients); the rest were retrospective case control studies (3557 patients). The influence of categorical BMI on pCR after NACT was analyzed. All studies provided data with BMI divided into two subgroups (BMI &lt;25 vs BMI ≥25). Pooled analyses demonstrated overweight/obese women were less likely to achieve pCR after NACT when compared with women in the under-/normal weight group, OR=0.77 (95% CI: 0.71, 0.84). 10 studies provided data with BMI divided into three groups (BMI &lt;25, 25 ≤BMI&lt; 30, BMI ≥30). Pooled analyses showed compared to under-/normal weight group, both overweight (OR= 0.81 95% CI: 0.72, 0.89) and obese (OR = 0.62 95% CI: 0.54, 0.69) groups were less likely to achieve pCR to NACT. We were not able to perform pooled analysis of association between BMI and pCR in subtypes of breast cancer based on hormone receptor and HER-2 status; as only two studies provided these data and breast cancer subtypes were defined differently. There was moderate heterogeneity in between these studies.
Conclusion: Overweight and obese breast cancer patients had lower pCR rates compared to those with under-/normal weight. Further prospective studies may help to confirm this finding and to clarify underlying mechanisms.
Citation Format: Haiyun Wang, Shijia Zhang, Douglas Yee, Heather Beckwith, David Potter, Anne Blaes. Pathological complete response following neoadjuvant chemotherapy in operable breast cancer patients: Is obesity a predictive factor? [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-08-39.
Abstract P3-08-54: Pattern of hepatic metastasis as a prognostic index in breast cancer liver metastasis
Authors: Lee Jieun , Choi Moon Hyung , Lee Ahwon , Lee Sung Hak 
Published: March 2020

Abstract
Background Liver is one of a common site of metastasis in metastatic breast cancer, and associated with visceral crisis in breast cancer. The clinical course and prognosis of breast cancer with liver metastasis (BCLM) is quite different with other solid cancers presenting with liver metastasis. BCLM patients frequently develop hepatic failure due to liver metastasis, but there are no clinicopathologic or radiologic parameters estimating the prognosis of BCLM during their clinical course. In this study, we analyzed the relationship of radiologic, clinicopathologic characteristics and survival outcomes in BCLM patients. Methods Between January 2009 to May 2019, 156 BCLM patients were analyzed. Baseline and final abdomen CT scan or liver MRI during treatment was reviewed by experienced radiologist. The pattern of liver metastasis was classified as oligometasis (3 or less metastatic lesions), non-confluent mass formation, confluent mass formation, infiltrative and pseudocirrhosis pattern. Clinicopathologic characteristics including child-pugh score (CPS) and survival outcomes including liver metastasis associated overall survival (LMOS) was analyzed Results Among 156 patients, 77 patients were initially presented with oligometastasis, 58 patients with non-confluent mass-forming pattern, 14 patients with confluent mass formation, and 7 patients with infiltrative liver metastasis. Patients who showed liver metastasis at initial recurrence or metastasis showed confluent mass-forming (9 patients, 64.3%) or infiltrative liver metastasis (6 patients, 85.7%) as presentation. At patient’s death, initial confluent mass-forming or infiltrative liver metastasis patients showed hepatic dysfunction with CPS 2 or 3. Patients with oligometastasis showed superior LMOS compared to non-confluent mass-forming, confluent mass-forming and infiltrative liver metastasis with worst survival outcome (median LMOS 55.03 months vs. 36.87, 36.93 and 8.8 months, P=0.0021). In luminal B patients, radiologic liver metastasis pattern at patient’s death or last follow-up were associated to cause of patient’s death such as hepatic failure (P=0.044). There were no survival benefit of patients who received local treatment for liver metastasis, compared to patients who only received systemic chemotherapy. Conclusion Initial hepatic metastasis pattern were associated with LMOS, especially infiltrative liver metastasis associated to poor survival outcome. There were no survival benefit of local treatment of liver metastasis during follow-up. Authors are planning on subsequent analysis based on pathologic classification of liver metastasis.
Citation Format: Jieun Lee, Moon Hyung Choi, Ahwon Lee, Sung Hak Lee. Pattern of hepatic metastasis as a prognostic index in breast cancer liver metastasis [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-08-54.
Abstract P3-08-61: The association of disease free survival and the impact of tumor subtype on overall survival in advanced breast cancer patients: A real-world study from the China National Cancer Center
Authors: Li Yiqun , Xu Binghe , Ma Fei , Li Qing , Zhang Pin , Yuan Peng , Wang Jiayu , Luo Yang , Cai Ruigang , Li Qiao , Mo Hongnan , Guan Xiuwen , Lin Shaoyan , Chen Yimeng , Wang Zijing 
Published: March 2020

Abstract
Objective: In breast cancer, tumor subtype and disease free survival (DFS) are correlated with prognosis. The aim of this study was to assess whether the effect of tumor subtype on survival was associated with DFS. Methods: The China National Cancer Center database was used to identify 1784 breast cancer women diagnosed between January 1987 to June 2017. Overall survival (OS) was defined as the time from first tumor recurrence or relapse to death due to any cause. Eligibility required metastatic patients with documented ER, PR, and HER2 status. Tumor subtype was classified into four groups: HR+HER2-, HR+HER2+, HR-HER2+ and triple negative breast cancer (TNBC) group. Results: In patients whose DFS &lt; 2 years, we found significant differences between tumor subtype and OS (P=0.007), with HR+HER2- presenting most favorable survival while TNBC showing worst prognosis. A similar pattern was observed in patients whose DFS &lt; 3, 4 and 5 years (all P&lt;0.001). However, when disease recurrence occurred within 1 year, no differences in survival were observed among tumor subtypes (P=0.508). Subsequent first-line treatment analysis in the overall ‘DFS&lt; 1 year’ group and the four subtype groups showed that combined chemotherapy did not significantly improve patient survival compared with single agent chemotherapy (all P&gt; 0.1). Of note, if DFS was longer than five years, the impact of different tumor subtype on survival was not obvious (P=0.438). Conclusion: No survival differences were found among tumor subtypes when DFS was shorter than one year, indicating particularly poor prognosis even in the HR+HER2- subtype, possibly due to primary treatment resistance. Subsequent more intensive first-line treatment with combined chemotherapy might not help in prolonging survival.
Citation Format: Yiqun Li, Binghe Xu, Fei Ma, Qing Li, Pin Zhang, Peng Yuan, Jiayu Wang, Yang Luo, Ruigang Cai, Qiao Li, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Yimeng Chen, Zijing Wang. The association of disease free survival and the impact of tumor subtype on overall survival in advanced breast cancer patients: A real-world study from the China National Cancer Center [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-08-61.
Abstract P3-11-19: Preclinical model of TNBC: Dasatinib attenuates Src pathway signaling and combined with veliparib and carboplatin potently inhibits tumor growth
Authors: Sun yuliang , Lin Xiaoqian , Aske Jennifer , Williams Casey , Abramovitz Mark , Leyland-Jones Brian 
Published: March 2020

Abstract
Background: The combination of a poly ADP ribose polymerase (PARP) inhibitor with a DNA-damaging agent has shown promise in treating triple-negative breast cancer (TNBC); however, not all patients respond to this combination. The Src protein kinase modulates multiple cancer cell properties and plays a key role in tumorigenic processes. However, Src inhibitors as single agents have shown limited effects in solid tumors. In this study, we examined the antitumor effects of the Src inhibitor dasatinib, the PARP inhibitor veliparib, and the DNA-damaging agent carboplatin in TNBC cells in vitro and tumors in vivo to try to identify the combination with the most clinical potential. Methods: The BRCA-mutated and PTEN null TNBC cell line, SUM149PT, was used in this study. For in vitro studies, proliferation, cellular apoptosis, and 3D on-top clonogenic growth were measured, tube formation assays and western blot analysis were performed. For in vivo studies, a xenograft model was used to examine treatment responses, and immunohistochemical analysis was performed. Results: Surprisingly, treatment with the combination of veliparib plus carboplatin led to an increase in Src phosphorylation. Importantly, addition of dasatinib attenuated Src overexpression induced by veliparib plus carboplatin and further inhibited the downstream signaling of Src, thereby enhancing the antitumor efficacy of veliparib plus carboplatin. In an SUM149PT xenograft model, the triple combination of dasatinib with veliparib plus carboplatin showed greater tumor growth inhibitory effects compared with single agents or double combinations. No systemic toxicity was observed in mice treated with the triple combination. Conclusion: Here, we provide novel evidence that veliparib combined with carboplatin drives Src activation in the preclinical model tested. Moreover, we provide provocative in vitro and in vivo data highlighting the potential for increasing therapeutic efficacy by combining dasatinib with veliparib and carboplatin in BRCA-mutated and PTEN null TNBC.
Citation Format: yuliang Sun, Xiaoqian Lin, Jennifer Aske, Casey Williams, Mark Abramovitz, Brian Leyland-Jones. Preclinical model of TNBC: Dasatinib attenuates Src pathway signaling and combined with veliparib and carboplatin potently inhibits tumor growth [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-11-19.